ClinicalTrials.gg
CompletedNCT01869686Updated Nov 6, 2014Results posted

Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose

A Phase 1 interventional study of Denosumab in Healthy Volunteer, sponsored by Amgen. Completed at 1 site in United States. Open to male participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-06.

Sponsored by Amgen · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Male
01

Study summary

This is a phase 1b, open-label, single dose study in healthy male subjects. Approximately 12 healthy male subjects will receive a subcutaneous injection of denosumab on Day 1. Subjects will be followed by a 105 day treatment-free follow-up period.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject has provided ; Healthy male between ≥40 to ≤ 65 years of age (inclusive) at the time of enrollment; Subject must be willing and able to produce a semen sample on seven separate study visits; Subject must be willing to refrain from ejaculation for a 48 hour period prior to each sample collection;

Exclusion criteria

Exclusion Criteria:

Any condition or drug therapy that might interfere with the subjects ability to ejaculate and produce a semen sample; abnormality during the screening physical examination, , or laboratory evaluation; Known history of blood in urine or semen; Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease; Recent tooth extraction (within 6 months of screening visit); Evidence of hypocalcemia at screening; Known vitamin D deficiency; (except non-melanoma skin cancers) within the last 5 years; Positive for (HIV) at screening or known diagnosis of AIDS; Positive Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B) or detectable virus Ribonucleic acid (RNA) by Polymerase Chain Reaction (PCR) at screening (indicative of active Hepatitis C - screening is generally done by Hepatitis C Antibody (HepCAb), followed by Hepatitis C virus RNA by PCR if HepCAb is positive); History of or allergic reaction to mammalian cell derived drug products or sensitivity to any of the products or components to be administered during dosing; Known intolerance to calcium or vitamin D supplements; Subject previously has entered this study or has been previously exposed to denosumab in the past 12 months; Has donated or lost ≥ 400 mL of blood or plasma within 8 weeks prior to screening; Positive urine screen for alcohol and/or potential drugs of abuse at screening unless medication is prescribed by a physician and approved by the Investigator and Amgen; Known alcohol abuse or use of illicit drugs within 12 months of enrollment; Subject is unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to screening and administration of product. Alcohol is limited to no more than 2 drinks per day for the duration of the study; where a standard drink is equivalent to 12 ounces of regular beer, 8-9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits; Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded; Use of any non-Amgen approved over-the-counter or prescription medications, within the 14 days or 5 half-lives (whichever is longer), prior to receiving the dose of denosumab. Acetaminophen (up to 2 g per day) for analgesia and hormone replacement therapy (eg, androgen, thyroid) will be allowed. Other medications may be approved following review by the Principal Investigator and the Amgen Medical Monitor. Written documentation of this review and Amgen acknowledgement is required for subject participation; Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge; Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written and/or to comply with all required study procedures; History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Denosumab

    single subcutaneous injection

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    60 mg

    Also known as: Prolia (R)

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  2. Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  3. Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid

    The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Denosumab in Serum

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  2. Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  3. Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum

    The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  4. Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)

    The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  5. Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period

    The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.

    Time frame: Days 1, 10, 22, 36, 50, 78 and 106

  6. Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).

    Time frame: Day 106

07

Results

Posted Sep 26, 2014

Participant flow

First patient enrolled 17 June 2013; last patient enrolled 17 June 2013.

Participant flow — Overall Study
MilestoneDenosumab
Started12
Completed12
Not completed0

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid
Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · ng/mL
Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid
ng/mLDenosumab
Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid100 ± 81.9
PrimaryTime to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid
Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Median · days
Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid
daysDenosumab
Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid21 ± 81.9
PrimaryArea Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid

The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.

Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · days*ng/mL
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid
days*ng/mLDenosumab
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid5220 ± 4880
SecondaryMaximum Observed Concentration (Cmax) of Denosumab in Serum
Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · ng/mL
Maximum Observed Concentration (Cmax) of Denosumab in Serum
ng/mLDenosumab
Maximum Observed Concentration (Cmax) of Denosumab in Serum6170 ± 2070
SecondaryTime to Maximum Observed Concentration (Tmax) of Denosumab in Serum
Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Median · days
Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum
daysDenosumab
Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum8.0 ± 81.9
SecondaryArea Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum

The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.

Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · days*ng/mL
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum
days*ng/mLDenosumab
Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum333000 ± 122000
SecondaryRatio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)

The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)

Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · ratio
Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)
ratioDenosumab
Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)0.0217 ± 0.0154
SecondaryRatio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period

The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.

Time frame:
Days 1, 10, 22, 36, 50, 78 and 106
Reported as:
Mean · ratio
Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period
ratioDenosumab
Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period0.0170 ± 0.0148
SecondaryRatio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).
Time frame:
Day 106
Reported as:
Mean · ratio
Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).
ratioDenosumab
Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).0.0197 ± 0.0318

Adverse events

Collected over 78 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 60 mg SC—1/12 (8.3%)5/12 (41.7%)
Most frequent serious events
Most frequent serious events
EventDenosumab 60 mg SC
Vertigo positionalEar and labyrinth disorders1/12
Most frequent other events
Most frequent other events
EventDenosumab 60 mg SC
Upper respiratory tract infectionInfections and infestations2/12
FallInjury, poisoning and procedural complications2/12
Musculoskeletal painMusculoskeletal and connective tissue disorders2/12
Rectal haemorrhageGastrointestinal disorders1/12
FatigueGeneral disorders1/12
Diabetes mellitusMetabolism and nutrition disorders1/12
HypercholesterolaemiaMetabolism and nutrition disorders1/12
HypophosphataemiaMetabolism and nutrition disorders1/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Denosumab
Mean56.6 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab
Female0
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab
American Indian or Alaska Native0
Asian0
Black (or African American)0
Mixed race0
Native Hawaiian or Other Pacific Islander0
White11
Othe1
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Denosumab
Mean27.73 ± 4.21
08

Study locations

1 site
  • Research Site
    Overland Park, Kansas 66212, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2013
First posted
Jun 5, 2013
Start
Jun 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 26, 2014
Last update
Nov 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01869686
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 5, 2013
Start date
Jun 2013
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 26, 2014
Last update
Nov 6, 2014

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion